437 related articles for article (PubMed ID: 35279121)
21. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.
Scopim-Ribeiro R; Machado-Neto JA; de Melo Campos P; Niemann FS; Lorand-Metze I; Costa FF; Olalla Saad ST; Traina F
Diagn Pathol; 2016 Mar; 11():28. PubMed ID: 26984174
[TBL] [Abstract][Full Text] [Related]
22. TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public database.
Pan X; Chang Y; Ruan G; Zhou S; Jiang H; Jiang Q; Huang X; Zhao XS
Clin Exp Med; 2024 Feb; 24(1):35. PubMed ID: 38349460
[TBL] [Abstract][Full Text] [Related]
23. TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes.
Gurnari C; Pagliuca S; Guan Y; Adema V; Hershberger CE; Ni Y; Awada H; Kongkiatkamon S; Zawit M; Coutinho DF; Zalcberg IR; Ahn JS; Kim HJ; Kim DDH; Minden MD; Jansen JH; Meggendorfer M; Haferlach C; Jha BK; Haferlach T; Maciejewski JP; Visconte V
Blood Adv; 2022 Jan; 6(1):100-107. PubMed ID: 34768283
[TBL] [Abstract][Full Text] [Related]
24. Somatic reversion impacts myelodysplastic syndromes and acute myeloid leukemia evolution in the short telomere disorders.
Schratz KE; Gaysinskaya V; Cosner ZL; DeBoy EA; Xiang Z; Kasch-Semenza L; Florea L; Shah PD; Armanios M
J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34343137
[TBL] [Abstract][Full Text] [Related]
25. Acute myeloid leukaemia: recent data on prognostic gene mutations, in relation to stratified therapies for elderly patients.
Soura EN; Karikas GA
J BUON; 2019; 24(4):1326-1339. PubMed ID: 31646775
[TBL] [Abstract][Full Text] [Related]
26. Analysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome.
Feng Y; Liang H; Han M; Luo X; Zhu Y; Liu B
Hematology; 2023 Dec; 28(1):2220222. PubMed ID: 37288803
[TBL] [Abstract][Full Text] [Related]
27. Clinical implications of copy number alteration detection using panel-based next-generation sequencing data in myelodysplastic syndrome.
Kim YJ; Jung SH; Hur EH; Choi EJ; Lee KH; Park HC; Kim HJ; Kwon YR; Park S; Lee SH; Chung YJ; Lee JH
Leuk Res; 2021 Apr; 103():106540. PubMed ID: 33667811
[TBL] [Abstract][Full Text] [Related]
28. Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.
Scopim-Ribeiro R; Machado-Neto JA; Campos Pde M; Silva CA; Favaro P; Lorand-Metze I; Costa FF; Saad ST; Traina F
Eur J Haematol; 2015 May; 94(5):413-8. PubMed ID: 25200248
[TBL] [Abstract][Full Text] [Related]
29. [TET2 as a gatekeeper for hematologic malignancies].
Muto H; Sakata-Yanagimoto M; Chiba S
Rinsho Ketsueki; 2015 Jun; 56(6):651-6. PubMed ID: 26256875
[TBL] [Abstract][Full Text] [Related]
30. Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.
Pan F; Wingo TS; Zhao Z; Gao R; Makishima H; Qu G; Lin L; Yu M; Ortega JR; Wang J; Nazha A; Chen L; Yao B; Liu C; Chen S; Weeks O; Ni H; Phillips BL; Huang S; Wang J; He C; Li GM; Radivoyevitch T; Aifantis I; Maciejewski JP; Yang FC; Jin P; Xu M
Nat Commun; 2017 Apr; 8():15102. PubMed ID: 28440315
[TBL] [Abstract][Full Text] [Related]
31. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
Ko M; Huang Y; Jankowska AM; Pape UJ; Tahiliani M; Bandukwala HS; An J; Lamperti ED; Koh KP; Ganetzky R; Liu XS; Aravind L; Agarwal S; Maciejewski JP; Rao A
Nature; 2010 Dec; 468(7325):839-43. PubMed ID: 21057493
[TBL] [Abstract][Full Text] [Related]
32. Acquired mutations in TET2 are common in myelodysplastic syndromes.
Langemeijer SM; Kuiper RP; Berends M; Knops R; Aslanyan MG; Massop M; Stevens-Linders E; van Hoogen P; van Kessel AG; Raymakers RA; Kamping EJ; Verhoef GE; Verburgh E; Hagemeijer A; Vandenberghe P; de Witte T; van der Reijden BA; Jansen JH
Nat Genet; 2009 Jul; 41(7):838-42. PubMed ID: 19483684
[TBL] [Abstract][Full Text] [Related]
33. Invariant phenotype and molecular association of biallelic
Awada H; Nagata Y; Goyal A; Asad MF; Patel B; Hirsch CM; Kuzmanovic T; Guan Y; Przychodzen BP; Aly M; Adema V; Shen W; Williams L; Nazha A; Abazeed ME; Sekeres MA; Radivoyevitch T; Haferlach T; Jha BK; Visconte V; Maciejewski JP
Blood Adv; 2019 Feb; 3(3):339-349. PubMed ID: 30709865
[TBL] [Abstract][Full Text] [Related]
34. TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.
Yun J; Ji YS; Jang GH; Lim SH; Kim SH; Kim CK; Bae SB; Won JH; Park SK
Curr Issues Mol Biol; 2021 Aug; 43(2):917-931. PubMed ID: 34449560
[TBL] [Abstract][Full Text] [Related]
35. Germline Predisposition to Myeloid Neoplasms: Diagnostic Concepts and Classifications.
Obiorah IE; Upadhyaya KD; Calvo KR
Clin Lab Med; 2023 Dec; 43(4):615-638. PubMed ID: 37865507
[TBL] [Abstract][Full Text] [Related]
36. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Bejar R; Lord A; Stevenson K; Bar-Natan M; Pérez-Ladaga A; Zaneveld J; Wang H; Caughey B; Stojanov P; Getz G; Garcia-Manero G; Kantarjian H; Chen R; Stone RM; Neuberg D; Steensma DP; Ebert BL
Blood; 2014 Oct; 124(17):2705-12. PubMed ID: 25224413
[TBL] [Abstract][Full Text] [Related]
37. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia.
Churpek JE; Pyrtel K; Kanchi KL; Shao J; Koboldt D; Miller CA; Shen D; Fulton R; O'Laughlin M; Fronick C; Pusic I; Uy GL; Braunstein EM; Levis M; Ross J; Elliott K; Heath S; Jiang A; Westervelt P; DiPersio JF; Link DC; Walter MJ; Welch J; Wilson R; Ley TJ; Godley LA; Graubert TA
Blood; 2015 Nov; 126(22):2484-90. PubMed ID: 26492932
[TBL] [Abstract][Full Text] [Related]
38. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
Naqvi K; Sasaki K; Montalban-Bravo G; Alfonso Pierola A; Yilmaz M; Short N; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Kanagal-Shamanna R; Patel K; Soltysiak KA; Kantarjian HM; Garcia-Manero G
Cancer; 2019 Jul; 125(13):2233-2241. PubMed ID: 30861111
[TBL] [Abstract][Full Text] [Related]
39. Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes.
Hamilton BK; Rybicki L; Hirsch C; Przychodzen B; Nazha A; Gerds AT; Hanna R; Kalaycio M; Sekeres MA; Sobecks R; de Lima M; Majhail NS; Maciejewski J
Bone Marrow Transplant; 2019 Aug; 54(8):1281-1286. PubMed ID: 30655603
[TBL] [Abstract][Full Text] [Related]
40. Consequences of mutant TET2 on clonality and subclonal hierarchy.
Hirsch CM; Nazha A; Kneen K; Abazeed ME; Meggendorfer M; Przychodzen BP; Nadarajah N; Adema V; Nagata Y; Goyal A; Awada H; Asad MF; Visconte V; Guan Y; Sekeres MA; Olinski R; Jha BK; LaFramboise T; Radivoyevitch T; Haferlach T; Maciejewski JP
Leukemia; 2018 Aug; 32(8):1751-1761. PubMed ID: 29795413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
